Affiliation:
1. Sun Yat-sen University Cancer Center
2. Guangdong Esophageal Cancer Institute
Abstract
Abstract
Background
Neoadjuvant chemoradiotherapy (NCRT) followed by surgery is a standard treatment for locally advanced esophageal squamous cell carcinomas (ESCCs). However, evolution of genome and immunogenome in ESCCs driven by NCRT remain incompletely elucidated.
Methods
We performed whole-exome sequencing of 51 ESCC tumors collected before and after NCRT, 36 of which were subjected to transcriptome sequencing.
Results
Clonal analysis identified clonal extinction in 13 ESCC patients wherein all pre-NCRT clones disappeared after NCRT, and clonal persistence in 9 patients wherein clones endured following NCRT. Clone-persistent patients showed higher pre-NCRT genomic intratumoral heterogeneity and worse prognosis than clone-extinct ones. In contrast to clone-extinct patients, clone-persistent patients demonstrated a high proportion of subclonal neoantigens within pre-treatment specimens. Transcriptome analysis revealed increased immune infiltrations and up-regulated immune-related pathways after NCRT, especially in clone-extinct patients. The number of T cell receptor-neoantigen interactions were higher in clone-extinct patients than clone-extinct ones. Decrease in T cell repertoire evenness positively correlated to the decreased number of clonal neoantigens after NCRT, especifically in clone-extinct patients.
Conclusions
We identified two prognosis-related clonal dynamic modes driven by NCRT in ESCCs. This study extended our knowledge in the field of ESCC genome and immunogenome evolutions driven by NCRT.
Publisher
Research Square Platform LLC
Reference44 articles.
1. Sung H, Ferlay J, Siegel RL et al. Global Cancer Statistics. 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71 (3): 209–249.
2. Global burden of oesophageal and gastric cancer by histology and subsite in 2018;Arnold M;Gut,2020
3. Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology;Ajani JA;J Natl Compr Canc Netw,2023
4. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification;Schneider PM;Ann Surg,2005
5. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future;McGranahan N;Cell,2017